Skip to main content
PHAT logo

Phathom Pharmaceuticals, Inc.

PHATNASDAQHealthcareBiotechnology

$6.92Today:- (-)1Y −42.13%

As of Oct 16, 2026 close

Market cap
$628.10M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$6.52$18.31
Volume (live)
-
Avg. volume (3M)
1.37M

Phathom Pharmaceuticals (PHAT) Income Statement

Phathom Pharmaceuticals reported revenue of $175.11M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 216.9% from $55.25M a year earlier. Phathom Pharmaceuticals posted a net loss of $221.25M, compared with a net loss of $334.33M a year earlier. Gross margin was 87.1% and operating margin -91.4%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $74.27M, up 88.0% from the same quarter a year earlier.

Phathom Pharmaceuticals Income Statement Analysis

Values in millions USD

Scroll to see more
Phathom Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue175.1155.250.680.000.000.000.000.00
Cost of Revenue22.607.970.170.620.520.300.010.00
Gross Profit152.5147.280.52-0.62-0.52-0.30-0.010.00
Operating Expenses
Research & Development32.7834.0849.9071.4472.3498.1599.270.02
Selling, General & Administrative279.72290.66117.93101.0062.7427.226.941.21
Operating Expenses312.50324.75167.83172.44135.08125.37106.221.23
Operating Income-159.99-277.47-167.31-172.44-135.08-125.67-106.22-1.23
Other Income/Expense
Interest Income7.0415.167.882.130.041.091.090.00
Interest Expense68.1272.0141.97-27.31-6.794.584.180.01
Other Income/Expense-61.26-0.01-34.28-25.28-8.80-3.40-148.92-0.06
Income
Income Before Tax-221.25-334.33-201.59-197.72-143.88-129.07-255.13-1.29
Income Tax Expense0.000.000.000.000.000.000.000.01
Net Income-221.25-334.33-201.59-197.72-143.88-129.07-209.74-1.29
Net Income - Continuous Operations-221.25-334.33-201.59-197.72-143.88-129.07-209.74-1.29
Net Income - Discontinued Operations--------
EBITDA-159.35-261.52-159.05-171.82-134.56-124.19-250.95-0.05
EBIT-159.99-262.32-167.31-172.44-135.08-125.67--
Depreciation & Amortization0.630.800.580.620.520.300.011.23
Earnings Per Share
Basic EPS-3.00-5.00-4.00-5.00-4.00-4.00-8.00-
Diluted EPS-3.00-5.00-4.00-5.00-4.00-4.00-8.00-
Basic Shares Outstanding72.9263.1851.2939.1237.0033.2324.738.58
Diluted Shares Outstanding72.9263.1851.2939.1237.0033.2324.738.58

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Phathom Pharmaceuticals Financial Statements

What was Phathom Pharmaceuticals's revenue in fiscal 2025?

Phathom Pharmaceuticals reported revenue of $175.11M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 216.9% from $55.25M a year earlier.

Is Phathom Pharmaceuticals profitable?

No. Phathom Pharmaceuticals reported a net loss of $221.25M in fiscal 2025. In fiscal 2024 it lost $334.33M.

What is Phathom Pharmaceuticals's operating margin?

Phathom Pharmaceuticals's operating income was −$159.99M on revenue of $175.11M in fiscal 2025, an operating margin of -91.4%, compared with -502.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition